AVITA MEDICAL INC (AVH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

AVH - AVITA MEDICAL INC

Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.34
Index:

Avita Medical is developing and marketing a range of regenerative skin products. It is headquartered in California and listed on the ASX and NASDAQ.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.98

16 Apr
2024

-0.160

OPEN

$3.00

-5.10%

HIGH

$3.08

761,348

LOW

$2.95

TARGET
$5.10 71.1% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . ARX . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
AVH: 1
Title FY24
Forecast
FY25
Forecast
EPS (cps) - 131.6 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-42.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx75.5 M
Book Value Per Share xxxxxxxxxxxxxxx56.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-57.3 M
Net Profit Margin xxxxxxxxxxxxxxx-70.56 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-54.16 %
Return on Invested Capital xxxxxxxxxxxxxxx-41.30 %
Return on Assets xxxxxxxxxxxxxxx-34.56 %
Return on Equity xxxxxxxxxxxxxxx-54.16 %
Return on Total Capital xxxxxxxxxxxxxxx-142.42 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-59.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx61 M
Total Debt xxxxxxxxxxxxxxx62 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx131 M
Price To Book Value xxxxxxxxxxxxxxx7.66

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx2.2 M
Capex % of Sales xxxxxxxxxxxxxxx2.89 %
Cost of Goods Sold xxxxxxxxxxxxxxx12 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx249 M
Research & Development xxxxxxxxxxxxxxx31 M
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

3

xxxxxxxxx xx xxxxxxxxxxx xxxx xxxx xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

12/04/2024

2

Upgrade to Accumulate from Hold

$5.40

81.21%

While management at Avita Medical has downgraded 1Q commercial revenue guidance by -27% to US$11m, Ord Minnett maintains its $5.40 target as the time value of money and a strong US dollar provide offsets.

The downgrade was due to the value analysis committee taking longer-than-anticipated and slowing the uptake of Recell for the recent label expansion for full-thickness skin defects, explains the broker.

New guidance implies 1Q commercial revenue will decline by -21% compared to Q4 2023.  The analyst lowers the 2024 revenue forecast by -4% to US$79m on the expectation of revenue growth later in 2024.

The broker upgrades its rating to Accumulate from Hold due to the recent share price decline.

FORECAST
Ord Minnett forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -47.60 cents.
Ord Minnett forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -21.70 cents.

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

AVH STOCK CHART